Life Seal Vascular Awarded $1.25M NSF SBIR Phase II Grant to Advance Cygnum™ Device Toward FDA Clinical Trials
This Phase II award is an important validation of our scientific progress and the commercial potential of our
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
IRVINE, CA, UNITED STATES, August 6, 2026 /EINPresswire.com/ — Life Seal Vascular, Inc. (LSV), a medical technology company developing innovative sealing solutions for endovascular aortic repair, has been awarded prestigious $1.25 million Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Science Foundation (NSF).
This critical non-dilutive funding allows LSV to further advance its R&D and engineering pipeline, while minimizing equity dilution for existing shareholders ahead of commercialization milestones. The award capital will directly support imminent preclinical development and pre-Investigational Device Exemption (pre-IDE) activities, rapidly accelerating the company’s regulatory pathway toward an FDA IDE clinical trial submission and approval.
The award serves as strong federal validation for the commercial and scientific merit of LSV’s proprietary Cygnum™ Aneurysm Sac Management Device (ASMD), which has recently undergone a first in human trial with excellent results. Used as an adjunct to conventional endografts, the Cygnum device targets endoleaks—the primary, multi-billion-dollar clinical failure point in endovascular abdominal aortic aneurysm repair (EVAR). By introducing a predictable approach to sac sealing, LSV is uniquely positioned to establish an entirely new product category within the vascular device industry.
“This Phase II award is an important validation of our scientific progress and the commercial potential of our platform,” said Matt Thompson, Co-Chief Executive Officer of Life Seal Vascular. “This competitive, non-dilutive support allows us to build meaningful company value while remaining focused on our mission to dramatically improve long-term outcomes for EVAR patients.”
This grant is supported by the U.S. National Science Foundation under Award No. 2537986.
About America’s Seed Fund powered by NSF
America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.5 billion that supports fundamental research and education across all fields of science and engineering. Learn more at seedfund.nsf.gov.
About Life Seal Vascular, Inc.
Life Seal Vascular develops proprietary sealing technologies designed to manage the aneurysm sac and address endoleaks, improving the long-term safety, durability, and clinical effectiveness of endovascular aortic repair. For more information, visit www.lifesealvascular.com.
Media Relations
Life Seal Vascular Inc.
+1 612-840-2723
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
